116 compounds · evidence graded A to F · prices per mg from in-stock offers
peptide and research product database
Search 116 research product identities by name, alias, market and form. Read source-reviewed notes and compare dated vendor packages.
research market · not for human use
These vendors sell compounds as research chemicals. Most are not FDA-approved.
| compound | evidence | US status | from | lowest $/mg | median $/mg | vendors | assays per lot |
|---|---|---|---|---|---|---|---|
| BPC-157 body protection compound 157 | rulemaking pending | $58.00 | $5.67 | $6.00 | 5 | 9× | |
| TB-500 thymosin β4 fragment | rulemaking pending | $59.99 | $6.00 | $7.75 | 2 | 9× | |
| KPV α-MSH fragment | rulemaking pending | $49.99 | $5.00 | $6.00 | 5 | 9× | |
| MOTS-c mitochondrial-derived peptide | rulemaking pending | $49.99 | $3.50 | $5.00 | 5 | 9× | |
| 5-Amino-1MQ NNMT inhibitor | research only | $59.99 | $1.20 | $2.60 | 4 | 9× | |
| LL-37 human cathelicidin | rulemaking pending | $80.00 | $16.00 | $17.00 | 2 | 10× | |
| Dihexa angiotensin IV analogue | rulemaking pending | $98.99 | $9.90 | $9.90 | 4 | 9× | |
| SLU-PP-332 ERR agonist | research only | $74.99 | $15.00 | $15.00 | 2 | 7× | |
| IGF-1 LR3 long-acting IGF-1 analogue | research only | $59.99 | $59.99 | $78.99 | 5 | 9× |
9 of 116 compounds. Prices are listed prices before codes and shipping; per mg uses the package’s labelled amount. Evidence grades describe published human evidence, not product quality.
how the grades work
evidence grades
- approved, strong human outcome data
- phase 2–3 human trials, not yet approved
- small or early human studies
- animal or cell studies only
- contradicted, unsafe, or identity problems
Graded on published human evidence by an editorial first pass that is awaiting expert review. Grades come from the literature; no vendor can pay for a grade or a ranking. editorial policy